IL-17 and IFN- in the establishment of the liver protection after vaccination with kunitz type molecule during Fasciola hepatica infection

SILVANE L; CELIAS D; MALETTO B; SANCHEZ VALELCILLO MF; CHIODETTI AL; ALLEMANDI DA; SANTIAGO PALMA; . CERVI L.

Mar del Plata

Congreso; LXIV REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI); 2016

SAIC-SAI-SAFE

(730) IL-17 AND IFN-γ IN THE ESTABLISHMENT OFTHE LIVER PROTECTION AFTER VACCINATION WITHKUNITZ TYPE MOLECULE DURING FASCIOLA HEPATICAINFECTION.Leonardo Silvane1, Daiana Celias1, Belkys Maletto1, MaríaFernanda Sánchez Vallecillo1, Ana Chiodetti1, SantiagoPalma2, Daniel Allemandi2, Laura Cervi1.1Departamento de Bioquímica Clínica. Facultad CienciasQuímicas. Universidad Nacional Córdoba, CIBICI-CONICET.Córdoba, Argentina. 2Departamento de Farmacia.Facultad de Ciencias Químicas. Universidad NacionalCórdoba, UNITEFA (CONICET), Córdoba, Argentina.The liver fluke Fasciola hepatica infect livestock worldwide.Fascioliasis is also a food borne disease with up to 17 millionhumans infected. The prevailing control strategy based on anthelminticdrugs is unsustainable due to widespread resistance;hence vaccination appears as an attractive option to pursue. Inour laboratory we tested the efficacy of a vaccine formulated withKunitz type molecule (KTM), an inhibitor of serine proteases witha key role in survival of the parasite, and CpG-ODN/Coa-ASC16,an adjuvant with capacity to induce Th1 and Th17 responses. Ourprevious data showed that the immunization with KTM/CpG-ODN/Coa-ASC16 (KTM-adjuvant) reduces the liver damage caused bythe infection in mice. In this study we are interested in studying theimmune response developed after immunization with the vaccine ininfected mice. BALB/c mice were subcutaneously immunized withKTM-adjuvant, CpG-ODN/Coa-ASC16 or saline buffer at day 0, 7and 14. One week after the last vaccination, mice were challengedorally with 6 F. hepatica metacercariae and euthanized 25 days afterinfection. Splenocytes from all group of mice where restimulated withKTM for 3 days, and cytokines were measured in the supernatantof cultures by ELISA. The immunization of mice with KTM-adjuvantpromoted a significant increase in IL-17 and IFN-γ production (p<0,05)by splenocytes or peritoneal cells (PC) of infected mice compared withthose immunized with the adjuvant alone or just infected. Besides,this vaccination induced a decrease in IL-10 production (p<0,05)by splenocytes compared to the levels found in cells of mice onlyinfected. Also, vaccination with KTM-adjuvant induced a substantialincrease in the percentage of F4/80 high CD11b high (defined asmacrophages) of the total live PC from infected mice. Our datasuggest that the exacerbated Th1 and Th17 responses found inperitoneum and spleen of mice immunized with KTM-adjuvant mayhave a role in the protection observed against F. hepatica.